Discovery of RMC-6291, a potent, orally bioavailable, covalent RAS(ON) G12C selective inhibitor
Authors:
- James CreggJCJames Cregg
- Kristof PotaKPKristof Pota
- Adrian L. GillAGAdrian L. Gill
- Elena S. KoltunEKElena S. Koltun
- 18 October 2024
- book chapter
- Published by Elsevier
- p. 277-308
Abstract
No abstract availableThis publication has 121 references indexed in Scilit:
- Recent progress in covalent warheads for in vivo targeting of endogenous proteinsBioorganic & Medicinal Chemistry, 2021
- Prediction of Chameleonic EfficiencyChemMedChem, 2021
- Solution Conformations Explain the Chameleonic Behaviour of Macrocyclic DrugsChemistry – A European Journal, 2020
- Exploiting Atropisomerism to Increase the Target Selectivity of Kinase InhibitorsAngewandte Chemie International Edition, 2015
- Improving on Nature: Making a Cyclic Heptapeptide Orally BioavailableAngewandte Chemie International Edition, 2014
- Atropisomerism and Axial Chirality in Heteroaromatic Compounds2012
- Revealing Atropisomer Axial Chirality in Drug DiscoveryChemMedChem, 2011
- The Challenge of Atropisomerism in Drug DiscoveryAngewandte Chemie International Edition, 2009
- Atropisomeric property of 1‐(2,6‐difluorobenzyl)‐3‐[(2R)‐amino‐2‐phenethyl]‐5‐(2‐fluoro‐3‐methoxyphenyl)‐6‐methyluracilChirality, 2005
- Enantiomerization of an atropisomeric drugChirality, 1996